When Novo Nordisk’s blockbuster weight loss drug Wegovy won approval in August 2025 to treat the fatty liver disease, some investors thought it would put competitive pressure on Madrigal Pharmaceuticals' liver-targeted therapy Rezdiffra. But it seems that Madrigal has managed to avoid that outcome.
It seems there’s room for two in the MASH market.
When Novo Nordisk’s blockbuster weight loss drug Wegovy won approval in August 2025 to treat …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with moderate…
Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the…
Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions and…
The medicine developed by the100-year old Danish drugmaker may impact patients' brains in surprising ways
Novo Nordisk released new data to underscore its pill's safety and effectiveness, while Trump is asked whether private plans…
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward…
